Deep Longevity and SquareOne Wellness partner on deep biomarkers of aging and longevity

Deep Longevity added SquareOne Wellness to its growing longevity network; SquareOne physicians will get training in longevity medicine and interpret the AgeMetric™ reports incorporating multiple aging clocks

Today, Deep Longevity Inc, a pioneer in deep biomarkers of aging and longevity, and SquareOne Wellness announced a collaboration to deploy an extensive range of AI-powered aging clocks. Deep Longevity is to develop and provide the customized predictors of human biological age to the network of SquareOne Wellness clinicians and to provide a training program in longevity medicine.

Deep Longevity is a fully-owned subsidiary of a public company, Regent Pacific Group Limited (SEHK:0575.HK). Deep Longevity developed and exclusively in-licensed a portfolio of granted and pending patents on aging clocks developed using the latest advances in artificial intelligence.

Deep Longevity aging clocks are supported by a number of academic publications summarized in a recent review titled "BioHorology and biomarkers of aging: Current state-of-the-art, challenges and opportunities"

"The traditional approach to preventative medicine is focused on preventing disease by diagnosing the symptoms early or reducing the risks of disease. The AI-guided longevity medicine goes much further then that and is focusing on tracking the person's rates of aging at many levels, identification of longevity bottlenecks, and utilizing the latest advances in science and technology to slow down or reverse biological and psychological aging. We are very happy to have SquareOne join the rapidly growing network of our research and clinical partners focused on providing customers with extra years of productive and happy life", said Alex Zhavoronkov, Chief Longevity Officer of Deep Longevity Inc. 

SquareOne Wellness has been on the forefront of total wellness in the treatment of addiction. SquareOne has a holistic approach to wellness and addiction whose goal is to help patients live happier, healthier and longer lives. Deep Longevity and SquareOne will partner to see the impact that the utilization of aging clocks has on continued recovery. "We are always looking for new tools to help our patients reach their full potential in their recovery and in their overall health and life. We believe that the addition of deep aging clocks will be an added tool in long term patient success", said Joshua Jones, Director of Patient Interactions of SquareOne Wellness.

In the scope of the partnership SquareOne Wellness physicians will be trained in deep aging clocks and will be able to provide their customers with AgeMetric™ reports and engage in advanced research to assess the performance of aging clocks in the context of continued recovery.

###

About Regent Pacific (SEHK:0575.HK)

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering.

http://www.regentpac.com/

About SquareOne Wellness.

SquareOne Wellness is an addiction and wellness clinic that focuses on recovery of opioid addiction and behavioral health. SOW focus is on helping patients look at every aspect of their health utilizing medically assisted treatment, behavioral health therapy and lifestyle changes to help sustain recovery and live healthier and longer lives. For more information, visit Squareonewellness.org.

About Deep Longevity, Inc

Deep Longevity has been acquired by Regent Pacific (SEHK:0575.HK), a publicly-traded company. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other experts AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of

the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers.

http://longevity.ai/

Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery

Insilico partners with Taisho Pharmaceutical on end-to-end AI-powered senolytic drug discovery. Leading Japanese pharmaceutical company to engage Insilico Medicine on research partnership in the discovery of novel molecules

Thursday, October 15, 2020 (9 am ET) - Insilico Medicine announced today that Taisho Pharmaceutical Co., Ltd. and Insilico have entered into a research collaboration to identify novel therapeutics against aging. Insilico Medicine will utilize both the target discovery and generative chemistry parts of its Pharma.AI platform in this collaboration. It will use its proprietary Pandomics Discovery Platform to identify novel targets for senolytic drugs and Chemistry42 platform for a molecular generation. This collaboration brings together Insilico's state-of-art artificial intelligence (AI) technologies in drug discovery with Taisho's expertise in drug development, aimed to extend the human healthspan.

'We're delighted to collaborate with Taisho pharmaceutical, a well-recognized leader in the pharmaceutical industry and healthcare sector. It is believed that aging is a universal phenomenon that we cannot stop. However, emerging scientific evidence has shown that one may be able to reverse some of the age-associated processes. Through this collaboration, we will adopt our AI-powered drug discovery suites together with Taisho's validation platform to explore the new space of anti-aging solutions', said Jimmy Yen-Chu Lin, PhD, CEO of Insilico Medicine Taiwan, a fully-owned subsidiary of Insilico Medicine

Under the terms of the agreement, Insilico Medicine will receive an upfront payment and milestone payments upon achievement of specified goals. Insilico Medicine will be responsible for early research phase target identification and molecular generation and Taisho will work collaboratively with Insilico in validating the results in various in vitro and in vivo assays. Taisho has the exclusive option to acquire Insilico's co-ownership of the successfully developed programs under agreed payment.

'It is our great honor to be collaborating with the scientists of Taisho Pharmaceutical, one of the top 100 pharmaceutical companies in the world operating since 1912. The high level of the scientists we are interfacing, and our previous successes in the application of the Pharma.AI platform for discovery of novel targets and molecules in fibrosis, and previous experience in senolytic drug discovery give us confidence that this collaboration will be successful', said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.

###

About Taisho Pharmaceutical Co., Ltd.

https://www.taisho.co.jp/global/

Media Contact

For further information, images or interviews, please contact: ai@insilico.com

About Insilico Medicine

Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website http://insilico.com/

Insights from the largest conference on aging research and drug discovery revealed

The 4-day, 7th Aging Research, and Drug Discovery on-site and online conference organized by the University of Copenhagen, Columbia University, and Deep Longevity scientists attracted over 2,500 delegates

 Wednesday, September 30th, Copenhagen, Denmark -- The laboratory of the biology of aging at the University of Copenhagen, is happy to reveal the online availability of the lectures from the 7th Aging Research, and Drug Discovery (ARDD2020) on-site and online conference organized by the University of Copenhagen, Columbia University, and Deep Longevity scientists. The consented video lectures are available at http://www.AgingPharma.org. 

"It took a small village to be able to complete our Aging Research and Drug Discovery meeting. Huge thanks to everyone at Insilico Medicine and Deep Longevity as well as my co-organizers Alex Zhavoronkov and Daniela Bakula. Also thanks to the CESA staff who helped with the local arrangements. Without all these people the conference would not have reached the level that we did. As a final note, I want to encourage everyone to keep a lookout for next year's meeting. This time hopefully we will be able to meet in person at Columbia University, New York City. ", said Morten Scheibye-Knudsen, MD, Ph.D., the chair of the 7th Aging Research, and Drug Discovery, and head of the biology of the aging laboratory at the center for healthy aging at the University of Copenhagen. 

In 2020 the conference brought together over 2,500 registered delegates from academia, industry, and the government over 4 days with over 70 speakers and panelists. 

"We believe that this is the largest aging research meeting focusing on drug discovery and development to date. I am very happy to see that over the past 7 years since we started the meeting in Basel, it has grown and the longevity industry has evolved, matured, and gained the attention of the pharmaceutical companies and the governments worldwide. Healthy longevity is a fundamental human need and we need to dramatically expand the industry to make people live longer and healthier", said Alex Zhavoronkov, Ph.D., co-founder of ARDD, CEO of Insilico Medicine, and Chief Longevity Officer of Deep Longevity. 

###

About 7th Annual Aging Research and Drug Discovery (ARDD)

The Annual Aging Research and Drug Discovery (ARDD) Conference is an annual scientific conference bringing together academic, government, and industry thought leaders in aging research and longevity biotechnology. Started in 2014 as part of MipTec and later as part of Basel Life Science Week in Basel, Switzerland, the conference grew over the years to become the largest academic and industry meeting spanning 4 days with over 2,500 delegates in 2020 chaired by Morten Scheibye-Knudsen, MD, Ph.D., Daniela Bakula, Ph.D., of the University of Copenhagen and Alex Zhavoronkov, Ph.D. of Deep Longevity and Insilico Medicine. The conference is different from the other events in the field as it focuses on the translational aspect of aging research and has substantial participation from the large pharmaceutical and biotechnology companies and leading clinical centers. In the past, executives from Novartis, Roche, Regeneron, and many other pharmaceutical companies presented their research in aging. The conference materials are available at http://www.AgingPharma.org.

Insilico releases Pandomics, AI-powered platform for Novel Therapeutic Target Discovery

 A novel end-to-end AI-hypothesis generation engine that seamlessly interprets OMICS and text-based data for the discovery and analysis of novel therapeutic targets

HONG KONG, Sept. 23, 2020 /PRNewswire/ -- Insilico Medicine announces the official release of Pandomics - a part of the Pharma.ai AI platform designed to empower pharmaceutical target and drug discovery pipelines. Research biologists and clinicians can use Pandomics to perform OMICS data analytics and interpretation without requiring any prior knowledge of computational biology or bioinformatics. Additionally, drug target identification and biomarker development specialists can generate powerful hypotheses and assess repositioning strategies by harnessing the power of Artificial Intelligence (AI).

Insilico Medicine started working on an engine for target identification back in 2014. Since then, the technology has been validated through several successful partnering initiatives with pharmaceutical companies and research organisations as well as through Insilico Medicine's own internal drug development programs.

Pandomics aims to be the go-to platform for all biologists and clinicians, working with various OMICS datasets, and to quickly analyse, interpret and visualise data effectively in order to classify patient cohorts more accurately. 

"At Insilico, we have developed a platform that hands the power of bioinformatics over to the researcher's hands. Biologists, clinicians and therapeutic target specialists, will gain a wide range of novel visual ways to interpret biological data. When designing the tool, we focused on storytelling in data analysis and providing guidance for each step," said Alexey Dubovenko, Product Director for Pandomics at Insilico Medicine.

"We recently used parts of the Pandomics platform in combination with Chemistry42, our generative chemistry platform and inClinico, our clinical trials prediction platform, to demonstrate that we can go from the nomination of disease of interest to novel disease targets, to compounds that are ready to enter IND-enabling studies in record time. We also collaborated with dozens of key opinion leaders in different disease areas to complete experimental validation of Pandomics. We are very happy to put this system into the hands of research scientists, drug discovery and development experts, and medical doctors interested in research and academic publishing," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine.

For further information, images or interviews, please contact: polly.firs@insilico.com.

About Insilico Medicine

Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website http://insilico.com/

International team identifies a new regulatory pathway in bladder cancer

 GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma. 

August 20th, 2020, Hong Kong - Researchers from Johns Hopkins University in collaboration with Insilico Medicine announce the publication of a new research paper titled "GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma" in Science Signaling. 

The KEAP1-NRF2 pathway plays a key role in cancer prevention and protective cellular responses to oxidative and electrophilic stress. In normal and premalignant tissues the signaling pathways activated by NRF2 prevent cancer initiation and progression, but in fully malignant cells disruption of the KEAP1-NRF2 pathway results in the transactivation of NRF2 target genes, consequently inducing cell proliferation and other phenotypic changes in cancer cells.

In this study, the researchers from John Hopkins University in collaboration with Insilico Medicine analyzed the protein GULP1 and its influence on the KEAP1-NRF2 pathway. The results demonstrated that GULP1 knockdown leads to tumor cell proliferation in vitro and enhanced tumor growth in vivo, as well as the resistance to cisplatin treatment. In parallel with decreased GULP1 expression, an increased expression of antioxidant genes in cisplatin-resistant cells was observed. Furthermore, low or no expression of GULP1 was observed in most cisplatin nonresponder cases. 

Together, the findings demonstrate that GULP1 is a KEAP1 binding protein that regulates KEAP1-NRF2 signaling in UCB, and that promoter hypermethylation of GULP1 is a potential mechanism of GULP1 silencing.

"I am extremely happy to see authors from Insilico Medicine on this important paper by one of the world's top research groups. While KEAP1-NRF2 pathway is a major signaling axis in bladder cancer and other solid malignancies, targeting of this complex pathway remains challenging. Building on the knowledge generated in this study, we will use novel computational platforms developed at Insilico Medicine, such as Pandomics, and its integral component called Target ID, to focus on identifying and validating novel compounds that could inhibit this signaling network with high specificity, efficacy and safety", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine.

###

For further information, images or interviews, please contact: ai@insilico.com

About Insilico Medicine

Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Since its inception, Insilico Medicine raised over $52 million, published over 70 peer-reviewed papers, applied for over 20 patents, and received multiple industry awards. Website http://insilico.com/

Deep Longevity Inc to collaborate with and launch aging clocks with Human Longevity Inc

Deep Longevity Inc to collaborate with and provide an extensive range of deep biomarkers of aging to Human Longevity Inc

Tuesday, 14th of July, 2020, San Diego, CA (9:00AM) -- Today, Deep Longevity Inc, a developer of deep biomarkers of human aging, and Human Longevity Inc announce a collaboration to deploy an extensive range of AI-powered aging clocks. Deep Longevity is to develop and provide the customized predictors of human biological age to the network of Human Longevity Inc concierge longevity clinicians. 

Deep Longevity is a longevity-focused artificial intelligence spin-off from Insilico Medicine, Inc, one of the global leaders in deep learning for drug discovery and biomarker development. Deep Longevity exclusively licensed a portfolio of granted and pending patents on aging clocks developed using the latest advances in artificial intelligence. 

Deep Longevity aging clocks are supported by a number of academic publications covering summarized in a recent review titled "Biohorology and biomarkers of aging: Current state-of-the-art, challenges and opportunities."

Human Longevity Inc recently published a research paper on a large cohort of healthy patients in the journal Proceedings of the National Academy of Sciences (PNAS) titled "Precision medicine integrating whole-genome sequencing, comprehensive metabolomics, and advanced imaging." Deep Longevity and Human Longevity will engage in research to validate the deep aging clocks on this cohort. 

###

About Deep Longevity, Inc

Deep Longevity is a global leader in deep learning for aging research specializing in the development of deep biomarkers of aging using clinical blood tests, transcriptomic, proteomic, epigenetic, microbiome, behavioral, wearable, imaging, and multiple other data types. The company holds exclusive licenses to a comprehensive IP portfolio including both granted and pending patents. The company provides a broad range of deep aging clocks to some of the world's most advanced longevity clinics and physicians and is developing a range of simple consumer applications to track the rate of aging at the individual level. The company is developing a comprehensive decision support system for physicians to enable the development of personalized longevity protocols utilizing the latest advances in longevity biotechnology. Website: http://www.DeepLongevity.com

About Human Longevity, Inc.

Human Longevity, Inc. is a genomics-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI's business focus includes the Health Nucleus, a genomic-powered, precision medicine center which uses whole-genome sequencing analysis, advanced imaging, and blood analytics, to deliver the most complete picture of individual health. For more information, visit http://www.humanlongevity.com.

About Health Nucleus

Health Nucleus clinics combine leading edge science with physicians who are experts in large data sets to interpret patients' data and guide them toward longer, healthier lives. Headquartered in San Diego, CA, Health Nucleus is revolutionizing precision health care with proprietary programs like 100+, a suite of annual tests, services and care that help preempt disease before symptoms arise. Health Nucleus uses whole genome sequencing analysis and advanced digital imaging along with personal biomarkers to deliver a complete picture of individual health. By harnessing 150 gigabytes of health data on each patient, Health Nucleus are able to pinpoint pre-symptomatic risks of cardiovascular disease, cancer, neurological disease and degradation, metabolic health status, and more. Health Nucleus is a subsidiary of Human Longevity, LLC

Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI

Insilico Medicine and Arctoris announced a technology partnership to jointly discover and profile new therapeutics against COVID-19 by combining robotics and AI

Thursday, 9th of July - Insilico Medicine, a biotechnology company developing an end-to-end drug discovery pipeline utilizing next-generation artificial intelligence, today announced a technology partnership with Arctoris, the world's first fully automated drug discovery platform, offering remotely accessible, pre-optimised and fully validated R&D processes for its partners and clients globally. The partnership enables the two companies to combine their unique strengths in AI-guided drug discovery for target identification and generative chemistry on the one hand, and robotics for rapid generation of high-quality cell-based, molecular and biochemical data on the other. The partnership propels the two companies' abilities to discover and validate novel molecules faster.

Contributing their strengths to the fight against COVID-19, the two companies utilized their unique state-of-the-art techniques to discover, synthesize, and profile a set of inhibitors for COVID-19 treatment. Insilico identified novel small molecules using its AI capabilities, with Arctoris rapidly evaluating the intended biological actions on its robotic platform. In a develop-test-refine loop, the partners iterated new molecules several times faster than the industry standard, providing unprecedented prospects for new drug discovery successes. The JAK inhibitor study profiled a set of potent inhibitors that can help patients by modulating the life-threatening cytokine storm caused by COVID-19.

"We are excited to announce our technology partnership with Insilico Medicine, a world-leader in AI-based drug discovery. We see tremendous value in combining our next-generation robotic platform with Insilico's unique capabilities in drug design. During the COVID-19 pandemic, time is of the essence, and this project demonstrates that together, we are able to accelerate the drug discovery process, and create and progress new drug candidates faster and cheaper," said Martin-Immanuel Bittner MD DPhil, Co-Founder & CEO of Arctoris.

"Arctoris developed an advanced robotics platform that can be used for a very broad spectrum of applications in drug discovery and biological data generation. We are very happy to partner with this Oxford-based company on our COVID-19 program. We discussed the collaboration for quite some time but this pandemic really highlighted the benefits of a close AI- and robotics- powered discovery integration," said Alex Zhavoronkov, PhD, founder, and CEO of Insilico Medicine.

Insilico and Arctoris have already been working together on BioTarget, a collaborative effort supported by Cancer Research UK to find new molecules for cancer treatment from partners globally, crowdsourcing the drug discovery process and making leading experimental tools accessible to researchers worldwide, thereby democratising the drug discovery ecosystem.

Further collaboration will focus on joint drug discovery projects in oncology, a field of particular interest to both Arctoris and Insilico, with their mission to eliminate age-related disease and promote healthy longevity.

For further information, images or interviews, please contact: ai@insilico.com.

###

About Insilico Medicine

Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 80 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Website http://insilico.com/.

For further information, images or interviews, please contact: Sian Marshall, Head of Office, media@arctoris.com

About Arctoris

Arctoris Ltd is an Oxford-based research company that is revolutionising drug discovery for biotechnology companies, pharmaceutical corporations and academia. Arctoris has established the world's first fully automated drug discovery platform, offering pre-optimised and fully validated R&D processes for its partners and customers globally. Accessible remotely, the platform provides on-demand access to a wide range of biochemical, cell biology and molecular biology assays conducted by robotics, enabling rapid, informed decision-making in basic biology, target validation, toxicology and phenotypic screening. These assay capabilities are accessed using a powerful online portal that streamlines experiment planning, ordering, tracking and data analysis. Thanks to the Arctoris platform, partners and clients can rapidly, accurately and cost-effectively perform their research and advance their drug discovery programmes.